MediciNova (MNOV) News Today → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free MNOV Stock Alerts $1.31 -0.01 (-0.76%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMediciNova, Inc. (NASDAQ:MNOV) Short Interest Down 26.0% in Aprilmarketbeat.com - April 27 at 7:20 AMStockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)americanbankingnews.com - April 21 at 2:14 AMMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)globenewswire.com - April 2 at 7:00 PMMediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japanfinanznachrichten.de - March 27 at 1:30 PMPre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…msn.com - March 27 at 8:30 AMMediciNova Gets Patent in Japan for Multiple Sclerosis-Related Treatmentmarketwatch.com - March 27 at 8:30 AMMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japantmcnet.com - March 27 at 8:30 AMMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japanglobenewswire.com - March 26 at 7:00 PMMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Societyglobenewswire.com - March 20 at 7:00 PMCompanies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growthfinance.yahoo.com - March 20 at 6:11 PMMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicologyglobenewswire.com - March 12 at 6:30 AMMNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…finance.yahoo.com - February 29 at 2:54 PMMedicinova Incmoney.usnews.com - February 28 at 6:13 PMMediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Chinafinanznachrichten.de - January 17 at 12:09 PMMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Chinafinance.yahoo.com - January 17 at 7:08 AMMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicologyfinance.yahoo.com - December 21 at 7:32 PMMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europemarkets.businessinsider.com - December 6 at 7:58 PMMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europefinance.yahoo.com - December 6 at 7:58 PMMNOV: Encouraging Phase 2 Glioblastoma Results Presented at SNO…finance.yahoo.com - November 27 at 1:15 PMThe past five years for MediciNova (NASDAQ:MNOV) investors has not been profitablefinance.yahoo.com - November 22 at 8:39 AMWhy Is Neuro-Oncology-Focused MediciNova Stock Trading Higher Today?msn.com - November 20 at 1:40 PMMediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncologyfinance.yahoo.com - November 19 at 6:40 PMMediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuriabenzinga.com - October 28 at 9:05 AMMediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuriafinance.yahoo.com - October 27 at 10:32 AMWe're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wiselyfinance.yahoo.com - October 12 at 12:32 PMMediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canadafinance.yahoo.com - October 10 at 10:29 PMMediciNova, Inc.: MediciNova Receives Gene Therapy Milestone Paymentfinanznachrichten.de - October 5 at 8:55 AMMediciNova Receives Gene Therapy Milestone Paymentfinance.yahoo.com - October 4 at 7:26 PMMNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model…finance.yahoo.com - September 29 at 1:48 PMMediciNova gains after nonclinical data for lead asset in lung injurymsn.com - September 28 at 9:16 AMMediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injuryfinance.yahoo.com - September 27 at 11:55 PMMNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury…finance.yahoo.com - August 21 at 5:24 PMMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncologyfinance.yahoo.com - August 17 at 10:15 PMMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europebenzinga.com - August 16 at 8:15 PMMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europefinance.yahoo.com - August 16 at 8:15 PMMedicinova (NASDAQ:MNOV) Rises on Key Patent Win in Europemsn.com - August 16 at 10:14 AMMediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europefinance.yahoo.com - August 15 at 11:25 PMMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europefinance.yahoo.com - August 14 at 8:39 PMMediciNova (NASDAQ:MNOV) Issues Quarterly Earnings Resultsmarketbeat.com - August 11 at 4:30 PMWith 49% ownership, MediciNova, Inc. (NASDAQ:MNOV) has piqued the interest of institutional investorsfinance.yahoo.com - July 23 at 1:54 PMTraders Cheer After Bank Stress Test Results, Lifting US Equity Futuresmsn.com - June 29 at 9:59 AMMediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meetingfinance.yahoo.com - June 29 at 9:59 AMHRT Financial LP Takes Position in MediciNova, Inc. (NASDAQ:MNOV)marketbeat.com - June 6 at 5:48 AMMNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotechfinance.yahoo.com - May 30 at 4:36 PMMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europefinance.yahoo.com - May 15 at 12:17 AMMediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europefinance.yahoo.com - May 14 at 7:17 PMMediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canadafinance.yahoo.com - April 30 at 8:16 PMMediciNova, Inc. (MNOV) Stock Historical Prices & Data - Yahoo Financefinance.yahoo.com - April 15 at 7:43 AMMedicinova Inc Common Stock (MNOV)nasdaq.com - March 31 at 8:16 AMMediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injuryfinance.yahoo.com - March 9 at 10:35 PM Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December. Get the name of the stock here >>> MNOV Media Mentions By Week MNOV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNOV News Sentiment▼0.800.32▲Average Medical News Sentiment MNOV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNOV Articles This Week▼30▲MNOV Articles Average Week Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RLYB News Today VHAQ News Today CELU News Today LTRN News Today EGRX News Today MURA News Today LABP News Today ANEB News Today IMMX News Today HCWB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNOV) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
